Last reviewed · How we verify

NCT06972732: TELOS

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Recruiting now Phase 4 Last updated 15 September 2025
What this trial tests

Phase 4 trial testing Metformin in Type 2 Diabetes in 204 participants. Currently enrolling.

Timeline
11 June 2025
Primary endpoint
1 October 2026
1 October 2026

Quick facts

Lead sponsorBoryung Pharmaceutical Co., Ltd
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment204
Start date11 June 2025
Primary completion1 October 2026
Estimated completion1 October 2026
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Boryung Pharmaceutical Co., Ltd — full company profile →

Who can join

19 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Boryung Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06972732.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing